Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 91Leukemia, Lymphocytic, Chronic, B-Cell 28Myelodysplastic Syndromes 18Recurrence 9Lymphoma, Mantle-Cell 9Leukemia, Biphenotypic, Acute 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Hematologic Neoplasms 6Lymphoma, Follicular 4Myeloproliferative Disorders 3Multiple Myeloma 3Anemia, Refractory, with Excess of Blasts 3Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, B-Cell 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Venentoclax 1Targeted Therapy 1Sarcoma, Myeloid 1

Interventions

Rituximab 5Specimen Handling 3Biopsy 3ibrutinib 2binimetinib 2Vemurafenib 2Cyclophosphamide 2Cladribine 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1obinutuzumab 1immunotoxin HA22 1fludarabine phosphate 1fludarabine 1encorafenib 1acalabrutinib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Spinal Puncture 1Radiotherapy 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Lenalidomide 1High-Energy Shock Waves 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × venetoclax × 90 days × Clear all
NCT06311227 2026-05-13

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡